Oxidation, inflammation and structural modifications;Oxidación, inflamación y modificaciones estructurales

Archivos de Bronconeumologia

Volumn 43, Issue SUPPL.1, 2007, Pages 18-29

  Núñez Naveira, Laura ^a   Montero Martínez, Carmen ^a   Ramos Barbón, David ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Apoptosis; Chronic bronchitis; Chronic obstructive pulmonary disease; Inflammation; Macrophages; Neutrophils; Oxidative stress; Pulmonary emphysema; Steroids; T lymphocytes

Indexed keywords

ANTIGEN; CHEMOKINE; CYTOKINE; OXIDOREDUCTASE; PROTEINASE; PROTEINASE INHIBITOR; RADICAL; STEROID; TOBACCO SMOKE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DAMAGE; CELL STRUCTURE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; EXTRACELLULAR MATRIX; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LUNG BLOOD VESSEL; LUNG PARENCHYMA; MACROPHAGE; NEUTROPHIL; OXIDATION; OXIDATION KINETICS; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEINASE INHIBITION; TH1 CELL;

EID: 34547699001     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S0300-2896(07)71169-9     Document Type: Article

References (110)

1. American Thoracic Society. Cigarette smoking and health. Am J Respir Crit Care Med. 1996;153:861-5.
2. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256-76.
3. Wood AM, Stockley RA. The genetics of chronic obstructive pulmonary disease. Respir Res. 2006;7:130.
4. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax. 1998;53:129-36.
5. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med. 1995;152:1666-72.
6. Tetley TD. New perspectives on basic mechanisms in lung disease. 6. Proteinase imbalance: its role in lung disease. Thorax. 1993;48:560-5.
7. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997;378:151-60.
8. Finlay GA, O'Driscoll LR, Russell KJ, D'Arcy EM, Masterson JB, FitzGerald MX, et al. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med. 1997;156:240-7.
9. Ohnishi K, Takagi M, Kurokawa Y, Satomi S, Konttinen YT. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest. 1998;78:1077-87.
10. Segura-Valdez L, Pardo A, Gaxiola M, Uhal BD, Becerril C, Selman M. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest. 2000;117:684-94.
11. Imai K, Dalal SS, Chen ES, Downey R, Schulman LL, Ginsburg M, et al. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am J Respir Crit Care Med. 2001;163:786-91.
12. Linden M, Rasmussen JB, Piitulainen E, Tunek A, Larson M, Tegner H, et al. Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. Am Rev Respir Dis. 1993;148:1226-32.
13. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med. 1997;155:449-53.
14. Rutgers SR, Postma DS, Ten Hacken NH, Kauffman HF, Van Der Mark TW, Koeter GH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax. 2000;55:12-8.
15. Qiu Y, Zhu J, Bandi V, Atmar RL, Hattotuwa K, Guntupalli KK, et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;168:968-75.
16. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:1304-9.
17. Hiemstra PS, Van Wetering S, Stolk J. Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium. Eur Respir J. 1998;12:1200-8.
18. Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986;89:370-3.
19. Lams BE, Sousa AR, Rees PJ, Lee TH. Immunopathology of the small-airway submucosa in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158:1518-23.
20. + cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:711-7.
21. Zhu J, Qiu YS, Majumdar S, Gamble E, Matin D, Turato G, et al. Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med. 2001;164:109-16.
22. Chanez P, Vignola AM, O'Shaugnessy T, Enander I, Li D, Jeffery PK, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med. 1997;155:1529-34.
23. Pizzichini E, Pizzichini MM, Gibson P, Parameswaran K, Gleich GJ, Berman L, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998;158:1511-7.
24. Grashoff WF, Sont JK, Sterk PJ, Hiemstra PS, De Boer WI, Stolk J, et al. Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. Am J Pathol. 1997;151:1785-90.
25. Sommerhoff CP, Caughey GH, Finkbeiner WE, Lazarus SC, Basbaum CB, Nadel JA. Mast cell chymase. A potent secretagogue for airway gland serous cells. J Immunol. 1989;142:2450-6.
26. Laurell CB, Eriksson S. The electrophoretic alpha 1-globulin pattern of serum in alpha 1-antitrypsin deficiency. Scand J Clin Lab Invest. 1963;15:132-40.
27. Eriksson S. Studies in alpha 1-antitrypsin deficiency. Acta Med Scand Suppl. 1965;432:1-85.
28. + T lymphocytes with FEV1. Am J Respir Crit Care Med. 1997;155:852-7.
29. + T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:822-6.
30. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994;265:528-30.
31. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 1994;370:650-2.
32. Saetta M, Mariani M, Panina-Bordignon P, Turato G, Buonsanti C, Baraldo S, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;165:1404-9.
33. + lymphocytes in patients with COPD. Chest. 2004;125:71-6.
34. Vernooy JH, Moller GM, Van Suylen RJ, Van Spijk MP, Cloots RH, Hoet PH, et al. Increased granzyme A expression in type II pneumocytes of patients with severe COPD. Am J Respir Crit Care Med. 2007;175:464-72.
35. Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, Sciurba FC, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med. 2001;164:469-73.
36. Cosio MG, Majo J, Cosio MG. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest. 2002;121:S160-5.
37. Agusti A, MacNee W, Donaldson K, Cosio M. Hypothesis: does COPD have an autoimmune component? Thorax. 2003;58:832-4.
38. Cosio MG. Autoimmunity, T-cells and STAT-4 in the pathogenesis of chronic obstructive pulmonary disease. Eur Respir J. 2004;24:3-5.
39. Enelow RI, Mohammed AZ, Stoler MH, Liu AN, Young JS, Lou YH, et al. Structural and functional consequences of alveolar cell recognition by CD8(+) T lymphocytes in experimental lung disease. J Clin Invest. 1998;102:1653-61.
40. Di Stefano A, Caramori G, Capelli A, Gnemmi I, Ricciardolo FL, Oates T, et al. STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur Respir J. 2004;24:78-85.
41. Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med. 1998;158:1277-85.
42. Majo J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J. 2001;17:946-53.
43. Babior BM. Oxygen-dependent microbial killing by phagocytes (first of two parts). N Engl J Med. 1978;298:659-68.
44. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol. 2000;279:L1005-28.
45. Rahman I, MacNee W. Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease. Thorax. 1996;51:348-50.
46. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med. 1997;156:341-57.
47. MacNee W. Oxidants/antioxidants and COPD. Chest. 2000;117:S303-17.
48. Richards GA, Theron AJ, Van der Merwe CA, Anderson R. Spirometric abnormalities in young smokers correlate with increased chemiluminescence responses of activated blood phagocytes. Am Rev Respir Dis. 1989;139:181-7.
49. Schunemann HJ, Muti P, Freudenheim JL, Armstrong D, Browne R, Klocke RA, et al. Oxidative stress and lung function. Am J Epidemiol. 1997;146:939-48.
50. Pierrou S, Broberg P, O'Donnell R, Pawlowski K, Virtala R, Lindqvist E, et al. Expression of genes involved in oxidative stress responses in airway epithelial cells of COPD smokers. Am J Respir Crit Care Med. 2006 [En prensa].
51. Heunks LM, Vina J, Van Herwaarden CL, Folgering HT, Gimeno A, Dekhuijzen PN. Xanthine oxidase is involved in exercise-induced oxidative stress in chronic obstructive pulmonary disease. Am J Physiol. 1999;277:R1697-704.
52. Corradi M, Majori M, Cacciani GC, Consigli GF, De'Munari E, Pesci A. Increased exhaled nitric oxide in patients with stable chronic obstructive pulmonary disease. Thorax. 1999;54:572-5.
53. Paredi P, Kharitonov SA, Leak D, Ward S, Cramer D, Barnes PJ. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162:369-73.
54. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med. 1995;332:1198-203.
55. Montuschi P, Kharitonov SA, Ciabattoni G, Corradi M, Van Rensen L, Geddes DM, et al. Exhaled 8-isoprostane as a new non-invasive biomarker of oxidative stress in cystic fibrosis. Thorax. 2000;55:205-9.
56. Li XY, Rahman I, Donaldson K, MacNee W. Mechanisms of cigarette smoke induced increased airspace permeability. Thorax. 1996;51:465-71.
57. Feldman C, Anderson R, Kanthakumar K, Vargas A, Cole PJ, Wilson R. Oxidant-mediated ciliary dysfunction in human respiratory epithelium. Free Radic Biol Med. 1994;17:1-10.
58. Tuder RM, Zhen L, Cho CY, Taraseviciene-Stewart L, Kasahara Y, Salvemini D, et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol. 2003;29:88-97.
59. Nyunoya T, Monick MM, Klingelhutz A, Yarovinsky TO, Cagley JR, Hunninghake GW. Cigarette smoke induces cellular senescence. Am J Respir Cell Mol Biol. 2006;35:681-8.
60. Drost EM, Selby C, Lannan S, Lowe GD, MacNee W. Changes in neutrophil deformability following in vitro smoke exposure: mechanism and protection. Am J Respir Cell Mol Biol. 1992;6:287-95.
61. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996;153:530-4.
62. Rahman I. Oxidative stress, transcription factors and chromatin remodelling in lung inflammation. Biochem Pharmacol. 2002;64:935-42.
63. Vitalis TZ, Kern I, Croome A, Behzad H, Hayashi S, Hogg JC. The effect of latent adenovirus 5 infection on cigarette smoke-induced lung inflammation. Eur Respir J. 1998;11:664-9.
64. Janoff A, Carp H, Laurent P, Raju L. The role of oxidative processes in emphysema. Am Rev Respir Dis. 1983;127:S31-8.
65. Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, Kensler TW, et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest. 2004;114:1248-59.
66. Kadonaga JT. Eukaryotic transcription: an interlaced network of transcription factors and chromatin-modifying machines. Cell. 1998;92:307-13.
67. Moodie FM, Marwick JA, Anderson CS, Szulakowski P, Biswas SK, Bauter MR, et al. Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kappaB activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB J. 2004;18:1897-9.
68. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005;352:1967-76.
69. Szulakowski P, Crowther AJ, Jiménez LA, Donaldson K, Mayer R, Leonard TB, et al. The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:41-50.
70. Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allerg Clin North Am. 2005;25:451-68.
71. Geneser F. Textbook of histology. Copenhagen: Munksgaard; 1986.
72. Murray JF. The normal lung: the basis for diagnosis and treatment of pulmonary disease. Philadelphia: Saunders; 1986.
73. Weibel ER, Vidone RA. Fixation of the lung by formalin steam in a controlled state of air inflation. Am Rev Respir Dis. 1961;84:856-61.
74. Weibel ER, Gómez DM. Architecture of the human lung. Use of quantitative methods establishes fundamental relations between size and number of lung structures. Science. 1962;137:577-85.
75. Weibel ER. Principles and methods for the morphometric study of the lung and other organs. Lab Invest. 1963;12:131-55.
76. Bolender RP, Hyde DM, Dehoff RT. Lung morphometry: a new generation of tools and experiments for organ, tissue, cell, and molecular biology. Am J Physiol. 1993;265:L521-48.
77. James AL, Hogg JC, Dunn LA, Pare PD. The use of the internal perimeter to compare airway size and to calculate smooth muscle shortening. Am Rev Respir Dis. 1988;138:136-9.
78. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med. 1968;278:1355-60.
79. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med. 1974;291:755-8.
80. Cosio M, Ghezzo H, Hogg JC, Corbin R, Loveland M, Dosman J, et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med. 1978;298:1277-81.
81. Saetta M, Turato G, Baraldo S, Zanin A, Braccioni F, Mapp CE, et al. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med. 2000;161:1016-21.
82. Saetta M, Ghezzo H, Kim WD, King M, Angus GE, Wang NS, et al. Loss of alveolar attachments in smokers. A morphometric correlate of lung function impairment. Am Rev Respir Dis. 1985;132:894-900.
83. Thurlbeck WM, Angus GE, Pare JP. Mucous gland hypertrophy in chronic bronchitis, and its occurrence in smokers. Br J Dis Chest. 1963;57:73-8.
84. Thurlbeck WM, Fraser RG, Bates DV. The correlation between pulmonary structure and function in chronic bronchitis, emphysema and asthma. Med Thorac. 1965;22:295-303.
85. Mitchell RS, Ryan SF, Petty TL, Filley GF. The significance of morphologic chronic hyperplastic bronchitis. Am Rev Respir Dis. 1966;93:720-9.
86. Scott KWM. An autopsy study of bronchial mucous gland hypertrophy in Glasgow. Am Rev Respir Dis. 1968;97:54-61.
87. Mitchell RS, Silvers GW, Dart GA, Petty TL, Vincent TN, Ryan SF, et al. Clinical and morphologic correlations in chronic airway obstruction. Aspen Emphysema Conf. 1968;9:109-23.
88. Takizawa T, Thurlbeck WM. Muscle and mucous gland size in the major bronchi of patients with chronic bronchitis, asthma, and asthmatic bronchitis. Am Rev Respir Dis. 1971;104:331-6.
89. Thurlbeck WM. Pathophysiology of chronic obstructive pulmonary disease. Clin Chest Med. 1990;11:389-403.
90. Reid LM. Measurement of bronchial mucous gland layer: a diagnostic yardstick in chronic bronchitis. Thorax. 1960;15:132-41.
91. Hamid Q, Cosio M, Lim S. Inflammation and remodeling in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2004;114:1479-81.
92. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152:S77-121.
93. Eidelman DH, Ghezzo H, Kim WD, Cosio MG. The destructive index and early lung destruction in smokers. Am Rev Respir Dis. 1991;144:156-9.
94. Vlahovic G, Russell ML, Mercer RR, Crapo JD. Cellular and connective tissue changes in alveolar septal walls in emphysema. Am J Respir Crit Care Med. 1999;160:2086-92.
95. Gough J. Discussion on the diagnosis of pulmonary emphysema: the pathological diagnosis of emphysema. Proc R Soc Med. 1952;45:576-7.
96. Laennec RTH. A treatise on the diseases of the chest and on mediate auscultation. 4th ed. London: Thomas; 1835.
97. Kim WD, Eidelman DH, Izquierdo JL, Ghezzo H, Saetta MP, Cosio MG. Centrilobular and panlobular emphysema in smokers. Two distinct morphologic and functional entities. Am Rev Respir Dis. 1991;144:1385-90.
98. Orsos F. Au uber das elastische gerauust der normalen under der emphysematosen lunge. Pathol Anat. 1907;41:95-121.
99. Snider GL, Hayes JA, Franzblau C, Kagan HM, Stone PS, Korthy AL. Relationship between elastolytic acitivity and experimental emphysema-inducing properties of papain preparations. Am Rev Respir Dis. 1974;110:254-62.
100. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997;277:2002-4.
101. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med. 2001;163:737-44.
102. Liebow AA. Pulmonary emphysema with special reference to vascular changes. Am Rev Respir Dis. 1959;80:67-93.
103. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000;106:1311-9.
104. Hale KA, Niewoehner DE, Cosio MG. Morphologic changes in the muscular pulmonary arteries: relationship to cigarette smoking, airway disease, and emphysema. Am Rev Respir Dis. 1980;122:273-8.
105. Wright JL, Lawson L, Pare PD, Hooper RO, Peretz DI, Nelems JM, et al. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease. The effect of oxygen and exercise. Am Rev Respir Dis. 1983;128:702-7.
106. Hale KA, Ewing SL, Gosnell BA, Niewoehner DE. Lung disease in long-term cigarette smokers with and without chronic air-flow obstruction. Am Rev Respir Dis. 1984;130:716-21.
107. Magee F, Wright JL, Wiggs BR, Pare PD, Hogg JC. Pulmonary vascular structure and function in chronic obstructive pulmonary disease. Thorax. 1988;43:183-9.
108. Barbera JA, Riverola A, Roca J, Ramírez J, Wagner PD, Ros D, et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994;149:423-9.
109. Peinado VI, Barbera JA, Abate P, Ramírez J, Roca J, Santos S, et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159:1605-11.
110. Peinado VI, Barbera JA, Ramírez J, Gómez FP, Roca J, Jover L, et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol. 1998;274:L908-13.